Brief: DiaMedica Therapeutics Announces FDA Clearance Of IND Application To Initiate Phase 2/3 Clinical Trial For Dm199 For Acute Ischemic Stroke
17/05/2021 13:57
May 17 (Reuters) - DiaMedica Therapeutics Inc DMAC.O :
* DIAMEDICA THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND
APPLICATION TO INITIATE PHASE 2/3 CLINICAL TRIAL FOR DM199 FOR
ACUTE ISCHEMIC STROKE
* DIAMEDICA THERAPEUTICS INC - INITIATING REMEDY2 - PIVOTAL
PHASE
2/3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
Source text for Eikon: ID:nBwbQcS9da
Further company coverage: DMAC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on DiaMedica Therapeutics
See all newsBrief: Diamedica Therapeutics Announces Enrollment Of 200Th Patient In Remedy2 Phase 2/3 Acute Ischemic Stroke Trial
DiaMedica Q2 net loss widen less than expected
DiaMedica Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Qualcomm, Robinhood
Brief: Diamedica Receives FDA Feedback On Dm199 Preeclampsia Nonclinical Program